Table 1.
Patients’ Characteristics.
| Survival Endpoint | Progression-Free Survival | Overall Survival |
|---|---|---|
| Number of patients1—n | 311 | 306 |
| Included lymph nodes—n | 475 | 462 |
| Events—n (%) | 94 (30.2%) | 58 (19.0%) |
| Follow-up (days)—median (IQR) | 1170 (798–1645) | 1197 (818–1656) |
| Data source—n (%) | ||
| Yale | 201 (64.6%) | 200 (65.4%) |
| TCIA | 110 (35.4%) | 106 (34.6%) |
| Sex—n (%) | ||
| Male | 253 (81.4%) | 249 (81.4%) |
| Female | 58 (18.6%) | 57 (18.6%) |
| Age (years)—mean (SD) | 60.61 (9.24) | 60.60 (9.28) |
| HPV status2—n (%) | ||
| Positive | 235 (75.6%) | 233 (76.1%) |
| Negative | 76 (24.4%) | 73 (23.9%) |
| Smoking—n (%) | ||
| Never-smoker | 76 (24.4%) | 76 (24.8%) |
| Smoker | 143 (46.0%) | 142 (46.4%) |
| Pack-years—median (IQR) | 20 (10–40) | 20 (10–40) |
| Pack-years unknown—n | 20 | 20 |
| Unknown | 92 (29.6%) | 88 (28.8 %) |
| T stage3—n (%) | ||
| T1 | 43 (13.8%) | 42 (13.7%) |
| T2 | 120 (38.6%) | 120 (39.2%) |
| T3 | 99 (31.8%) | 97 (31.7%) |
| T4 | 49 (15.8%) | 47 (15.4%) |
| N stage3—n (%) | ||
| N0 | 60 (19.3%) | 59 (19.3%) |
| N1 | 149 (47.9%) | 149 (48.7%) |
| N2 | 97 (31.2%) | 94 (30.7%) |
| N3 | 5 (1.6%) | 4 (1.3 %) |
| Overall stage3—n (%) | ||
| I | 117 (37.6%) | 117 (38.2%) |
| II | 91 (29.3%) | 91 (29.7%) |
| III | 50 (16.1%) | 47 (15.4%) |
| IV | 53 (17.0%) | 51 (16.7%) |
| Included lymph nodes/patient—range | 0–8 | 0–8 |
| Primary treatment—n (%) | ||
| CCRT or CBRT | 208 (66.9%) | 204 (66.7%) |
| RT alone | 28 (9.0%) | 27 (8.8%) |
| Surgery | ||
| Without adjuvant therapy | 13 (4.2%) | 13 (4.2%) |
| With adjuvant RT, CCRT, or CBRT | 62 (19.9%) | 62 (20.3%) |
| PET4—mean (SD) | ||
| Slice thickness (mm) | 3.40 (0.38) | 3.39 (0.38) |
| In-plane pixel spacing (mm) | 4.30 (0.91) | 4.30 (0.92) |
| In-plane image matrix (n × n) | 147.16 (58.88) × idem | 147.32 (59.34) × idem |
| CT4—mean (SD) | ||
| Slice thickness (mm) | 3.12 (0.55) | 3.10 (0.54) |
| In-plane pixel spacing (mm) | 1.12 (0.18) | 1.12 (0.18) |
| In-plane image matrix (n × n) | 512 × 512 | 512 × 512 |
1 After exclusion of patients with uneventful follow-up <18 months from each respective study arm, subject counts differ in the progression-free survival (PFS) and overall survival (OS) cohorts. 2 The American Joint Committee on Cancer (AJCC) staging, demographics, treatment, and imaging characteristics of human papillomavirus (HPV)-associated and HPV-negative subjects are separately reported in Tables S1 and S2. 3 AJCC 8th edition staging manual T/N/overall stage [9]. 4 Values are from original images before pre-processing. CBRT = concurrent bioradiotherapy with cetuximab; CCRT = concurrent platinum-based chemoradiotherapy; IQR = interquartile range; RT = radiotherapy; SD = standard deviation; TCIA = The Cancer Imaging Archive.